Table 2 Deregulated expression of CDC20 and its involvement as prognostic and therapeutic target in hematological malignancies

ATL

CDC20 over-expression in ATL samples compared with normal CD4⁺ T cells.

Aberrant activation of APC/C^CDC20 induced by Tax

[116, 117]

AML

CDC20 over-expression in aneuploid and complex karyotype patients.

[118, 119]

CLL

CDC20 over-expression in aggressive subtypes (U-CLL and CD38⁺ CLL).

[120, 121]

CML

CDC20 stabilization induced by CDH1down-regulation in imatinib-resistance patients

[122]

DLBCL

CDC20 over-expression

Inferior OS

proTAME induces prolonged metaphase and caspase-dependent apoptosis. Combination of proTAME with Apcin, doxorubicin and venetoclax show synergic effects.

[123, 124]

MCL

CDC20 over-expression

Inferior OS

proTAME induces prolonged metaphase and caspase-dependent apoptosis. Combination of proTAME with Apcin, doxorubicin and venetoclax show synergic effects.

[124, 125]

MDS

CDC20 over-expression in high-risk patients

Shorter RFS and inferior OS

[126,127,128]

MM

CDC20 over-expression in cell lines and high-risk patients

Inferior OS

proTAME treatment induced G2/M arrest and increased apoptosis. Combination with etoposide and doxorubicin, vincristine or melphalan potentiated proTAME effect.

[129,130,131,132]